Page header

Recommendation of the President – Calquence (acalabrutinib)

On 27 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 10/2026 on the reimbursement of the medicinal product Calquence (acalabrutinib) under the B.79 drug program “Treatment of patients with chronic lymphocytic leukemia (ICD-10: C91.1)”

Publication in Public Information Bulletin (BIP) >>